D. Rudolph

发表

Activating Transcription Factor 1 and CREB Are Important for Cell Survival during Early Mouse Development

J. Blendy, G. Schütz, S. Bleckmann, 2002, Molecular and Cellular Biology.

CREB regulates hepatic gluconeogenesis through the coactivator PGC-1

Marc Montminy, P. Puigserver, B. Spiegelman, 2001, Nature.

BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity

G. Adolf, C. Haslinger, D. Rudolph, 2009, Clinical Cancer Research.

Erratum: CREB regulates hepatic gluconeogenesis through the coactivator PGC-1 (Nature (2001) 413 (179-183))

P. Puigserver, B. Spiegelman, M. Montminy, 2001 .

Severe liver degeneration and lack of NF - k B activation in NEMO/IKK g -deficient mice

T. Mak, A. Wakeham, A. Elia, 2000 .

correction: CREB regulates hepatic gluconeogenesis through the coactivator PGC-1

P. Puigserver, B. Spiegelman, M. Montminy, 2001, Nature.

Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo.

I. Waizenegger, Daniel Gerlach, N. Kraut, 2018, Cancer letters.

Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice.

T. Mak, A. Wakeham, A. Elia, 2000, Genes & development.

Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRASG12C Inhibitor

A. Waterson, D. Rudolph, M. Gmachl, 2022, Journal of medicinal chemistry.

CREB function is required for normal thymic cellularity and post‐irradiation recovery

B. Kyewski, P. Krammer, S. Baumann, 2004, European journal of immunology.

Discovery of Novel Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2-p53 Interaction.

Markus J. Bauer, P. Ettmayer, D. Rudolph, 2016, Journal of medicinal chemistry.

DR5 Knockout Mice Are Compromised in Radiation-Induced Apoptosis

S. Lowe, T. Mak, T. Burns, 2005, Molecular and Cellular Biology.

The role of nuclear factor-κB essential modulator (NEMO) in B cell development and survival

Tak W. Mak, T. Mak, D. Rudolph, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6.

M. Koegl, P. Ettmayer, T. Voss, 2017, Cell reports.

Efficacy and Mechanism of Action of Volasertib, a Potent and Selective Inhibitor of Polo-Like Kinases, in Preclinical Models of Acute Myeloid Leukemia

J. Zuber, Christoph Sommer, D. Gerlich, 2015, The Journal of Pharmacology and Experimental Therapeutics.

Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan.

I. Waizenegger, T. Heffernan, N. Kraut, 2021, Clinical Trials.

Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases

I. Waizenegger, G. Adolf, C. Haslinger, 2016, Molecular Cancer Therapeutics.

Chemically Induced Degra dation of the Oncogenic Transcription Factor BCL 6 Graphical Abstract Highlights

M. Koegl, P. Ettmayer, T. Voss, 2022 .

Targeted Synthesis of Complex Spiro[3H‐indole‐3,2′‐pyrrolidin]‐2(1H)‐ones by Intramolecular Cyclization of Azomethine Ylides: Highly Potent MDM2–p53 Inhibitors

Julian E. Fuchs, Joachim Broeker, D. Rudolph, 2018, ChemMedChem.

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

E. de Stanchina, Y. Pourfarjam, N. Kraut, 2023, Nature.

712 POSTER In vivo efficacy of BI 2536, a potent and selective inhibitor of the mitotic kinase Plk1, in human hematopoietic cancers

D. Rudolph, A. Baum, 2007 .

Impaired fetal T cell development and perinatal lethality in mice lacking the cAMP response element binding protein.

P. Gass, G. Schütz, D. Rudolph, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Deficits in memory tasks of mice with CREB mutations depend on gene dosage.

U. Frey, H. Lipp, P. Gass, 1998, Learning & memory.

Abstract 4866: BI 907828: A novel, potent MDM2 inhibitor that induces antitumor immunologic memory and acts synergistically with an anti-PD-1 antibody in syngeneic mouse models of cancer

C. Haslinger, D. Rudolph, P. Garin‐Chesa, 2018, Experimental and Molecular Therapeutics.

Abstract 4865: BI 907828: A highly potent MDM2 inhibitor with low human dose estimation, designed for high-dose intermittent schedules in the clinic

C. Haslinger, N. Kraut, D. Rudolph, 2018, Experimental and Molecular Therapeutics.

Abstract 4868: BI 907828: A novel, potent MDM2 inhibitor that is suitable for high-dose intermittent schedules

C. Haslinger, D. Rudolph, P. Garin‐Chesa, 2018 .

BI-907828, a novel potent MDM2 inhibitor, inhibits GBM brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models.

D. Rudolph, X. Hao, H. A. Luchman, 2022, Neuro-oncology.